```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued
 NEWS 20  APR 15  WPIDS, WPINDEX, and WPIX enhanced with new
                  predefined hit display formats

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:00:01 ON 27 APR 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:00:17 ON 27 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2008 HIGHEST RN 1017464-96-8
DICTIONARY FILE UPDATES: 25 APR 2008 HIGHEST RN 1017464-96-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s SKI-606
           176 SKI
             2 SKIS
           178 SKI
                 (SKI OR SKIS)
          4832 606
L1           1 SKI-606
                 (SKI(W)606)

=> d scan l1

L1   1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
     7-[3-(4-methyl-1-piperazinyl)propoxy]-
MF   C26 H29 Cl2 N5 O3
CI   COM
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s "SKI 606"
           176 "SKI"
             2 "SKIS"
           178 "SKI"
                 ("SKI" OR "SKIS")
          4832 "606"
L2           1 "SKI 606"
                 ("SKI"(W)"606")

=> d scan

L2   1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
     7-[3-(4-methyl-1-piperazinyl)propoxy]-
MF   C26 H29 Cl2 N5 O3
CI   COM
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


ALL ANSWERS HAVE BEEN SCANNED


=> file caplus medline embase biosis scisearch
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  23.82      24.03

FILE 'CAPLUS' ENTERED AT 17:04:21 ON 27 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:04:21 ON 27 APR 2008

FILE 'EMBASE' ENTERED AT 17:04:21 ON 27 APR 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:04:21 ON 27 APR 2008
Copyright (c) 2008 The Thomson Corporation
```

FILE 'SCISEARCH' ENTERED AT 17:04:21 ON 27 APR 2008

=> s l2
L3 235 L2

=> d scan l3

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI A novel 4-anilino-3-quinolinecarbonitrile dual src and abl kinase inhibitor (SKI-606) has in vitro activity on CML Ph plus Blast cells resistant to imatinib.
IT Miscellaneous Descriptors
apoptosis; cell viability; cell cycle progression

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 1-0 (Pharmacology)
TI Dual Src and Abl kinase inhibitor treatment of solid tumors treatment of CML and Ph+ ALL
ST review bosutinib solid tumor chronic myelogenous acute lymphoblastic leukemia
IT Acute lymphocytic leukemia
Chronic myeloid leukemia
Human
(dual Src and Abl kinase inhibitor bosutinib could be useful in treatment of solid tumors, chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in human)
IT Neoplasm
(solid; dual Src and Abl kinase inhibitor bosutinib could be useful in treatment of solid tumors, chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in human)
IT 98037-52-6, Abl kinase 141349-89-5, Src kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dual Src and Abl kinase inhibitor bosutinib could be useful in treatment of solid tumors, chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in human)
IT 380843-75-4, Bosutinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual Src and Abl kinase inhibitor bosutinib could be useful in treatment of solid tumors, chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in human)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
IT Methods & Equipment
homology modelling: mathematical and computer techniques; inhibitor binding analysis: laboratory techniques

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM C12N
CC 1-6 (Pharmacology)
Section cross-reference(s): 3, 7, 14
TI Binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs
ST binding inhibitory assay BCRABL kinase mutation antileukemic drug sensitivity; human sequence BCRABL protein kinase mutation

IT Chimeric gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(BCR-ABL; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Enzyme functional sites
(active; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Acute lymphocytic leukemia
Acute myeloid leukemia
Antitumor agents
Chemotherapy
Chronic myeloid leukemia
Drug resistance
Human
Protein sequences
(binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Molecular association
(inhibitor-kinase domain interaction; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Protein motifs
(kinase motif, mutations at; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Animal cell
(mammalian, expressing BCR-ABL polypeptide; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Diagnosis
(mol.; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT Mutation
(substitution; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT 936654-11-4 936654-12-5 936654-13-6 936654-14-7 936654-15-8
936654-16-9 936654-17-0
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT 152459-95-5, Imatinib 287204-45-9, PD180970 302962-49-8 379231-04-6, AZD0530 380843-75-4, SKI606 497152-38-2, CGP76030
641571-10-0, AMN107 845895-51-4, AP23464
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT 98037-52-6, ABL protein kinase
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(inhibitors of; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT 72-19-5, L-Threonine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(position 315, mutated to Ala; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT 63-91-2, L-Phenylalanine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(position 317, mutated to Ile, Val, Ser or Leu; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT 936663-40-0 936663-41-1 936663-42-2 936663-43-3 936663-44-4
936663-45-5 936663-46-6
RL: PRP (Properties)
(unclaimed nucleotide sequence; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)
IT 936663-47-7 936663-48-8 936663-49-9 936663-50-2 936663-51-3
936666-03-4 936666-04-5
RL: PRP (Properties)
(unclaimed sequence; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI A Dual Src/Abl Kinase Inhibitor Causes Regression of CML Xenografts in Nude Mice.
IT Miscellaneous Descriptors
drug resistance mechanism; tumor regression

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 63-6 (Pharmaceuticals)
TI Ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification
ST ocular device kinase inhibitor coating posterior capsule opacification
IT Cell migration
Coating materials
Controlled-release drug delivery systems
Epithelium
Eye, disease
Mesenchyme
Ophthalmic drug inserts
Pharmaceutical implants
(ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)
IT Fibronectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)
IT Opacity
(opacification, eye disease; ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)
IT α-Actins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(smooth muscle; ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)
IT 142243-02-5, ERK 165245-96-5, p38 Kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)
IT 172889-26-8, PP1
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)
IT 109511-58-2, U0126 152121-30-7, SB202190 152121-47-6, SB203580 167869-21-8, PD98059 330161-87-0, SU6656 380843-75-4, SKI606
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ocular device coated with kinase inhibitors to treat and prevent posterior capsule opacification)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2008:162804 SCISEARCH
GA The Genuine Article (R) Number: 237TE
TI Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer.
CC ONCOLOGY

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM A61K
CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 21
TI Protection of tissues and cells from cytotoxic effects of ionizing radiation by ABL inhibitors
ST radioprotectant ABL protein kinase inhibitor
IT Antioxidants
Human
Radioprotectants
Radiotherapy
(ABL protein kinase inhibitors as radioprotectants)
IT Carotenes, biological studies
Flavanols
Flavonoids
Phenols, biological studies
Porphyrins
Ubiquinones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)
IT Transplant and Transplantation
(bone marrow; ABL protein kinase inhibitors as radioprotectants)
IT Drug delivery systems
(carriers; ABL protein kinase inhibitors as radioprotectants)
IT Flavones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(isoflavones; ABL protein kinase inhibitors as radioprotectants)
IT Flavonoids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxo dihydro; ABL protein kinase inhibitors as radioprotectants)
IT Bone marrow
(transplant; ABL protein kinase inhibitors as radioprotectants)
IT 98037-52-6, ABL protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ABL protein kinase inhibitors as radioprotectants)
IT 152459-95-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)
IT 334969-03-8 334969-21-0 334969-29-8 592542-77-3 592542-83-1 851799-24-1 851799-25-2 851799-26-3 851799-27-4 851799-28-5

851799-29-6 851799-30-9 851799-31-0 851799-32-1 851799-33-2
851799-34-3 851799-35-4 851799-36-5 851799-37-6 851799-38-7
851799-39-8 851799-40-1 851799-41-2 851799-42-3 851799-47-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

IT 88-68-6 109-01-3, 1-Methylpiperazine 124-63-0, Methanesulfonyl chloride 350-03-8 367-21-5, 3-Chloro-4-fluoroaniline 1194-65-6 1783-81-9, 3-Methylthioaniline 3943-74-6 4432-76-2 5909-24-0 7357-67-7 13794-72-4 33524-31-1 98446-49-2, 2,4-Dichloro-5-methoxyaniline 148077-69-4 152460-07-6 152460-09-8 152460-10-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(ABL protein kinase inhibitors as radioprotectants)

IT 54105-05-4P 111627-40-8P 179688-52-9P 179688-53-0P 184475-71-6P 185039-29-6P 185039-46-7P 185039-48-9P 185040-32-8P 192997-47-0P 214470-59-4P 214470-66-3P 214470-68-5P 230955-75-6P 788136-89-0P 859504-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(ABL protein kinase inhibitors as radioprotectants)

IT 140674-78-8P 184475-35-2P 260415-63-2P 380843-75-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

IT 50-81-7, Ascorbic acid, biological studies 52-90-4, Cysteine, biological studies 60-24-2, β-Mercaptoethanol 70-18-8, Glutathione, biological studies 616-91-1, N-Acetyl-L-cysteine 1406-18-4, Vitamin E 3483-12-3, Dithiothreitol 20537-88-6 23288-49-5, Probucol 25769-03-3, 1-Pyrrolidinecarbodithioic acid 112675-73-7 112676-08-1 137515-05-0 140674-76-6 151391-94-5 152459-77-3 152459-78-4 152459-79-5 152459-80-8 152459-82-0 152459-83-1 152459-84-2 152459-86-4 152459-87-5 152459-88-6 152459-89-7 152459-90-0 152459-91-1 152459-93-3 152459-94-4 152459-96-6 152459-97-7 152459-98-8 152459-99-9 152460-06-5 156790-79-3 156790-80-6 158081-87-9 158081-88-0 158081-89-1 185039-91-2 287204-45-9 305820-77-3 592542-59-1 592542-82-0 592543-23-2 592543-24-3 851799-48-9 851799-49-0 851799-50-3 851799-51-4 859504-11-3 859504-12-4 859504-13-5 859504-14-6 859504-15-7 859504-16-8 859504-17-9 859504-18-0 859504-19-1 859504-20-4 859504-21-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:364683 SCISEARCH
GA The Genuine Article (R) Number: 111GS
TI In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic
CC HEMATOLOGY

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
TI 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as Dual Inhibitors of Src and Abl Kinases
ST quinolinecarbonitrile arylaminopiperidinylmethoxy prepn Src Abl kinase inhibitor

IT 98037-52-6, Abl kinase 141349-89-5, Src kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as inhibitors of Src and Abl kinases)

IT 380843-75-4P, SKI606 622368-88-1P 622368-90-5P 622368-91-6P

622368-93-8P 622369-16-8P 622369-17-9P 622369-18-0P 622369-19-1P
622369-20-4P 622369-21-5P 622369-26-0P 681819-24-9P 681821-34-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as inhibitors of Src and Abl kinases)
IT 94-05-3, Ethyl (ethoxymethylene)cyanoacetate 95-68-1, 2,4-Dimethylaniline 106-52-5, 1-Methyl-4-piperidinol 366-99-4, 3-Fluoro-4-methoxyaniline 554-00-7, 2,4-Dichloroaniline 2401-24-3, 2-Chloro-5-methoxyaniline 5317-33-9, 1-(3-Hydroxypropyl)-4-methylpiperazine 7037-30-1, 1-Methyl-4-piperidinepropanol 7583-53-1, 1-Methyl-3-piperidinemethanol 20691-89-8, 1-Methyl-4-piperidinemethanol 20845-34-5, 1-Methyl-2-piperidinemethanol 21156-84-3, 1-Methyl-4-piperidineethanol 24313-88-0, 3,4,5-Trimethoxyaniline 50868-72-9, 5-Methoxy-2-methylaniline 98446-49-2, 2,4-Dichloro-5-methoxyaniline 380844-01-9, 2,4-Dichloro-5-ethoxyaniline 380844-06-4, 5-Methoxy-2,4-Dimethylaniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as inhibitors of Src and Abl kinases)
IT 622369-38-4P 622369-40-8P 622369-46-4P 622369-54-4P 622369-75-9P
622369-76-0P 622369-77-1P 622369-78-2P 622369-79-3P 681819-23-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as inhibitors of Src and Abl kinases)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2006:892418 SCISEARCH
GA The Genuine Article (R) Number: 083YN
TI Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling
CC CHEMISTRY, MEDICINAL
STP KeyWords Plus (R): RECEPTOR TYROSINE KINASE; NON-HODGKINS-LYMPHOMA; BCR-ABL; CELL LYMPHOMA; POTENT INHIBITORS; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; FUSION PROTEIN; C-ABL; ALK
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI SKI-606, a novel Src kinase inhibitor, blocks migration and invasion of human breast cancer cells.
IT Miscellaneous Descriptors
cell invasion; cell migration

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM A61K
CC 1-5 (Pharmacology)
Section cross-reference(s): 7
TI Method of treating inflammatory diseases using tyrosine kinase inhibitors
ST tyrosine kinase inhibitor inflammatory disease therapy
IT Inflammatory bowel disease
(Crohn's disease; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgM; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(IκB-α (NF-κB inhibitor α); treating inflammatory diseases using tyrosine kinase inhibitors)
IT Transcription factor STAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT1; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Transcription factor STAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT3; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Transcription factor STAT
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT5; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Autoimmune disease
(autoimmune arthritis; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Arthritis
(autoimmune; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-Raf; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-abl; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-jun; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Autoimmune disease
(exptl. autoimmune encephalomyelitis; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Encephalomyelitis
(exptl. autoimmune; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Lung, disease
(fibrosis; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Cell differentiation
(monocyte lineage cell; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Interleukin 12
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p40; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Phosphorylation, biological
(protein; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Arthritis
(psoriatic arthritis; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Fibrosis
(pulmonary; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Macrophage
(synovial; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Synovial membrane
(synoviocyte, fibroblast-Like; treating inflammatory diseases using

tyrosine kinase inhibitors)
IT Lupus erythematosus
(systemic; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Anti-inflammatory agents
Antiarthritics
Antirheumatic agents
Apoptosis
Arthritis
Autoimmune disease
B cell (lymphocyte)
Combination chemotherapy
Human
Inflammation
Mast cell
Multiple sclerosis
Oral drug delivery systems
Psoriasis
Rheumatoid arthritis
Scleroderma
Signal transduction
T cell (lymphocyte)
(treating inflammatory diseases using tyrosine kinase inhibitors)
IT Epidermal growth factor receptors
Interleukin 1α
Interleukin 2
Interleukin 4
Interleukin 6
Macrophage colony-stimulating factor receptors
Platelet-derived growth factor receptors
Tumor necrosis factors
c-Kit (protein)
neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treating inflammatory diseases using tyrosine kinase inhibitors)
IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-1; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-2; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-3; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β; treating inflammatory diseases using tyrosine kinase inhibitors)
IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ; treating inflammatory diseases using tyrosine kinase inhibitors)
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(Gleevec; treating inflammatory diseases using tyrosine kinase inhibitors)

IT 80449-02-1, Protein tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treating inflammatory diseases using tyrosine kinase inhibitors)

IT 63551-76-8, Phospholipase Cγ 81627-83-0, M-CSF 83869-56-1, Granulocyte-macrophage colony-stimulating factor 90698-26-3, p70s6K 114051-78-4, Lck kinase 141349-89-5, Src kinase 144697-16-5, b-Raf 147230-71-5, Flt3 kinase 148640-14-6 149371-05-1, c-Abl 152478-56-3, JAK1 kinase 155215-87-5, JNK 165245-96-5, p38 MAP kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treating inflammatory diseases using tyrosine kinase inhibitors)

IT 111358-88-4, Lestaurtinib 120685-11-2, PKC412 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 152459-94-4, CGP53716 183321-74-6, Erlotinib 184475-35-2, Gefitinib 185039-91-2, PD166326 187724-61-4, PKI-166 194413-58-6, Semaxanib 212141-54-3, Vatalanib 231277-92-2, Lapatinib 251356-32-8, SU9518 252916-29-3, SU6668 257933-82-7, EKB-569 284461-73-0, Sorafenib 288383-20-0, Cediranib 302962-49-8, Dasatinib 319460-85-0, Axitinib 379231-04-6, AZD0530 380843-75-4, SKI-606 387867-13-2, Tandutinib 443913-73-3, Vandetanib 444731-52-6, Pazopanib 453562-69-1, AMG 706 557795-19-4, Sunitinib 641571-10-0, Nilotinib 679809-58-6, Enoxaparin 692737-80-7, CHIR258 870483-87-7, GW2580 936487-63-7, CP 690
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating inflammatory diseases using tyrosine kinase inhibitors)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI Activity of ABL kinase inhibitors in two distinct models of imatinib resistance.
IT Miscellaneous Descriptors
drug resistance

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1
TI Application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs
ST tyrosine kinase inhibitor dibenzocyclooctadiene lignan antitumor agent synergistic interaction
IT Antitumor agents
(2C4; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
(D816X; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
(PD0173074; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
(PK1166; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
Combination chemotherapy
Controlled-release drug delivery systems
Human
Neoplasm
Pharmaceutical capsules
Pharmaceutical granules

Pharmaceutical injections
Pharmaceutical tablets
Schisandra chinensis
(application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Endothelium
(of human umbilical vein; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Drug interactions
(synergistic; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Animal cell line
(tumor; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT 7432-28-2, Schisandrol A 51670-40-7, Kadsurin 51670-41-8, Kadsurarin 58546-54-6, Schisandrol B 58546-55-7, Schisantherin B 58546-56-8, Schisantherin A 60546-10-3, Gomisin D 61281-37-6, Schisandrin B 61281-38-7, Schisandrin A 61301-33-5, Schisandrin C 62956-47-2, Gomisin F 62956-48-3, Gomisin G 64917-82-4, Schisantherin D 64917-83-5, Schisantherin E 64938-51-8, Schisantherin C 66056-20-0, Gomisin H 66056-22-2, Angeloylgomisin H 66056-23-3, Benzoylgomisin H 66069-55-4, Tigloylgomisin H 66096-73-9 66096-74-0, Methylschisandrol E 66280-25-9, Gomisin J 69176-51-8, Tiglogomisin P 69176-52-9, Gomisin N 69363-14-0, Gomisin K3 72561-28-5, Angeloylgomisin Q 72960-21-5, Gomisin E 72960-22-6, Gomisin O 73036-31-4, Epigomisin O 75629-20-8, Gomisin K1 75706-12-6, SU101 77165-79-8, Binankadsurin A 77165-80-1 77165-81-2 77174-33-5, Acetylbinankadsurin 77881-08-4, Angelogomisin P 82425-45-4, Gomisin M2 82467-50-3, Gomisin M1 82467-52-5, Isokadsuranin 83864-69-1 83864-70-4 83864-71-5, Benzoylisogomisin O 83864-72-6, Gomisin R 87084-98-8, Neoisostegane 95152-96-8 111358-88-4, CEP-701 115181-68-5, Neokadsuranin 117047-86-6, Schisantherin G 117047-87-7, Schisantherin H 117047-88-8, Schisantherin F 117073-94-6, Schisantherin I 119139-55-8, Interiorin 120685-11-2, PKC412 128324-09-4, Angeloylgomisin R 129385-73-5, Benzoylgomisin Q 129445-43-8 130252-41-4 130252-42-5, Propoxyloxokadsurane 130252-43-6 130252-44-7 130252-45-8 130783-32-3 135432-28-9, Schisantherin J 135541-43-4, Benzoylbinankadsurine A 135541-44-5, Isovaleroylbinankadsurin A 135541-45-6, Isobutyroylbinankadsurin A 143625-35-8, Schisantherin K 149990-51-2, Schisantherin L 149990-52-3, Schisantherin M 150132-86-8, Schisantherin N 150132-87-9, Schisantherin O 180288-69-1, Trastuzumab 183321-74-6, Erlotinib 184475-35-2, Gefitinib 204005-46-9, SU5416 205256-55-9, CT52923 205923-56-4, Erbitux 212142-18-2, PTK787 215543-92-3, SU5402 216974-75-3, Bevacizumab 220127-57-1, Gleevec 231277-92-2, GW-572016 252916-29-3, SU6668 260415-63-2, PD173955 284461-73-0, BAY43-9006 287204-45-9, PD180970 289499-45-2, CI-1033 302962-49-8, BMS354825 339177-26-3, ABX-EGF 341031-54-7, SU11248 379231-04-6, AZD0530 380843-75-4, SKI606 387867-13-2, MLN518 497152-38-2 641571-10-0, AMN107 790713-55-2, AZD 6474 845895-51-4, AP23464 871919-08-3 871919-11-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT 80449-02-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI SKI-606 decreases growth and motility of colorectal cancer cells by

preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
IT Methods & Equipment
immunoblotting: laboratory techniques, immunologic techniques; immunofluorescence staining: laboratory techniques, histology and cytology techniques, immunologic techniques
IT Miscellaneous Descriptors
cell-to-cell adhesion; transcriptional-adhesive function switch

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 1-0 (Pharmacology)
TI New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance
ST review chronic myelogenous leukemia dasatinib nilotinib bosutinib imatinib antitumor
IT Drug resistance
(antitumor; dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)
IT Antitumor agents
Chronic myeloid leukemia
Combination chemotherapy
Human
(dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)
IT Antitumor agents
(resistance to; dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)
IT 152459-95-5, Imatinib 302962-49-8, Dasatinib 380843-75-4, Bosutinib 641571-10-0, Nilotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
IT Miscellaneous Descriptors
K562 xenografts: regression

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
INCL 514221000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
TI Combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent for treating cancer
ST antitumor combination BCR ABL inhibitor stem cell selective cytotoxic
IT Chimeric gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(BCR-ABL; antitumor combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent)
IT Antitumor agents
Chronic myeloid leukemia

Combination chemotherapy
Philadelphia chromosome-positive leukemia
Stem cell
(antitumor combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent)
IT 152459-95-5, Imatinib 195987-41-8 302962-49-8 379231-04-6, AZD0530 380843-75-4, SKI 606 641571-10-0, AMN-107 845895-51-4, AP23464
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:698492 SCISEARCH
GA The Genuine Article (R) Number: 186FK
TI Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606
CC ONCOLOGY; HEMATOLOGY
ST Author Keywords: chronic myloid leukemia; p210 tyrosine kinase (TK); SRC kinases; cyclin-dependent kinase 2 (Cdk2); phosphatidylinositol 3 kinase (PI-3k)/Akt
STP KeyWords Plus (R): CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; CYCLE PROGRESSION; DEPENDENT PHOSPHORYLATION; PHILADELPHIA-CHROMOSOME; INTERLEUKIN-3 RECEPTOR; PROGENITOR CELLS; AKT ACTIVATION; IMATINIB
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 1-6 (Pharmacology)
TI SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models
ST colorectal cancer SKI 606 Src Abl
IT Antitumor agents
Human
(SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor xenograft models)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-abl; SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor xenograft models)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-src; SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor xenograft models)
IT Intestine, neoplasm
(colon; SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor xenograft models)
IT 380843-75-4, SKI-606
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor xenograft models)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:362672 SCISEARCH
GA The Genuine Article (R) Number: 111GS
TI A phase 1/2 study of SKI-606, a dual inhibitor of src and abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib.

CC HEMATOLOGY

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM C07D215-38
ICS C07D215-60
INCL 546153000; 546159000
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 45
TI Process for the preparation of 7-substituted 3-quinoline and 3-quinol-4-one carbonitriles via nucleophilic substitution
ST quinoline quinolone carbonitrile prepn halogenation alkylation amine nucleophilic substitution; quinolinecarbonitrile quinolonecarbonitrile prepn halogenation alkylation amine nucleophilic substitution
IT Alkylation
Halogenation
Substitution reaction, nucleophilic
(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT Nitriles, preparation
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(quinoline product; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT Amines, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT 7646-69-7, Sodium hydride 7693-26-7, Potassium hydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(base; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT 7440-09-7, Potassium, reactions 7440-23-5, Sodium, reactions
RL: RGT (Reagent); RACT (Reactant or reagent)
(base; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT 7789-59-5, Phosphoric tribromide 10025-87-3, Phosphoric trichloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(halogenating agent; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT 221198-59-0P, 2-Fluoro-1-(2-methoxyethoxy)-4-nitrobenzene 221199-26-4P, 3-Fluoro-4-(2-methoxyethoxy)aniline 423180-28-3P, 4-Chloro-6-methoxy-7-[(1-methyl-piperidin-4-yl)methoxy]quinoline-3-carbonitrile 622369-35-1P 622369-36-2P 622369-37-3P 622369-38-4P 622369-40-8P 622369-42-0P 622369-44-2P 622369-46-4P 622369-48-6P 622369-49-7P 622369-50-0P 622369-51-1P 622369-52-2P 622369-53-3P 622369-54-4P 622369-55-5P 622369-56-6P 622369-57-7P 622369-59-9P 622369-60-2P 622369-62-4P 622369-63-5P 622369-65-7P 622369-66-8P 622369-67-9P 622369-68-0P, Ethyl 2-[[(1E)-(dimethylamino)methylidene]amino]-4-fluorobenzoate 622369-69-1P 622369-70-4P 622369-71-5P 622369-73-7P 622369-74-8P 622369-75-9P 622369-76-0P 622369-77-1P 622369-78-2P 622369-79-3P 622369-82-8P 622369-84-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT 622369-64-6P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)
IT 622369-72-6P, 7-(2-Methoxyethoxy)-4-oxo-1,4-dihydroquinoline-3-

carbonitrile
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 87-13-8, Diethylethoxymethylene malonate 94-05-3, Ethyl(ethoxymethylene)cyanoacetate 100-72-1, Tetrahydropyran-2-methanol 109-01-3, N-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-86-4, 2-(Methoxy)ethanol 111-77-3, 2-(2-Methoxyethoxy)ethanol 139-59-3, 4-Phenoxyaniline 366-99-4, 3-Fluoro-4-methoxyaniline 446-32-2, 2-Amino-4-fluorobenzoic acid 554-00-7, 2,4-Dichloroaniline 622-40-2, 4-(2-Hydroxyethyl)morpholine 626-64-2, 4-Hydroxypyridine 636-72-6, 2-Thiophenemethanol 764-01-2, 2-Butyn-1-ol 930-69-8, Sodium thiophenoxide 1003-03-8, Cyclopentylamine 1188-33-6, Dimethylformamide diethyl acetal 3179-63-3 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 5317-33-9, 3-[(4-Methyl)piperazin-1-yl]propanol 6482-24-2, 2-Bromoethyl methyl ether 7583-53-1, 1-Methylpiperidine-3-methanol 13349-82-1, 2-[2-(1-Piperazinyl)ethoxy]ethanol 19059-68-8, 3-Dimethylamino-2,2-dimethyl-1-propanol 20691-89-8, (1-Methylpiperidin-4-yl)methanol 21156-84-3, 1-Methyl-4-piperidineethanol 22510-08-3, 2-Fluoro-5-nitrophenol 24313-88-0, 3,4,5-Trimethoxyaniline 80650-45-9, 4-(Pyridin-3-yloxy)phenylamine 98446-49-2, 2,4-Dichloro-5-methoxyaniline 168268-00-6, 4-Benzyloxy-3-fluoroaniline 205194-33-8, 3-(1,1-Dioxothiomorpholinyl)-1-propanol 622369-58-8 622369-61-3 622369-80-6 622369-81-7, 1-Ethyl-4-(3-hydroxypropyl)piperazine 622369-83-9, 3-(1-Methylpiperidin-4-yl)propylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 380843-75-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]quinoline-3-carbonitrile 622368-76-7P 622368-77-8P 622368-78-9P 622368-79-0P 622368-80-3P 622368-81-4P 622368-82-5P 622368-83-6P 622368-84-7P 622368-85-8P 622368-86-9P 622368-87-0P 622368-88-1P 622368-89-2P 622368-90-5P 622368-91-6P 622368-92-7P 622368-93-8P 622368-94-9P 622368-95-0P 622368-96-1P 622368-97-2P 622368-98-3P 622368-99-4P 622369-00-0P 622369-01-1P 622369-02-2P 622369-03-3P 622369-04-4P 622369-05-5P 622369-06-6P 622369-07-7P 622369-08-8P 622369-09-9P 622369-10-2P 622369-11-3P 622369-12-4P 622369-13-5P 622369-14-6P 622369-15-7P 622369-16-8P 622369-17-9P 622369-18-0P 622369-19-1P 622369-20-4P 622369-21-5P 622369-22-6P 622369-23-7P 622369-24-8P 622369-25-9P 622369-26-0P 622369-27-1P 622369-28-2P 622369-29-3P 622369-30-6P 622369-31-7P 622369-32-8P 622369-33-9P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[[3-(morpholin-4-yl)propyl]amino]quinoline-3-carbonitrile 622369-34-0P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(quinoline product; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2005:1238736 SCISEARCH
GA The Genuine Article (R) Number: 986CG
TI Gene expression profile in the CML cell line K562 treated with SKI-606, a dual inhibitor of Src/Abl kinase.
CC HEMATOLOGY

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase.

```
IT   Methods & Equipment
        flow cytometry: laboratory techniques, histology and cytology
        techniques
IT   Miscellaneous Descriptors
        apoptosis

L3    235 ANSWERS   CAPLUS  COPYRIGHT 2008 ACS on STN
CC   1-6 (Pharmacology)
TI   Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide
     compound for the treatment of leukemia
ST   antitumor cSrc protein tyrosine kinase inhibitor pyrimidylaminobenzamide
     combination leukemia
IT   Antitumor agents
     Chronic myeloid leukemia
     Combination chemotherapy
     Drug delivery systems
     Human
     Leukemia
     Veterinary medicine
        (use of c-Src inhibitors in combination with pyrimidylaminobenzamides
        for treatment of leukemia)
IT   144697-17-6, c-Src protein tyrosine kinase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitors; use of c-Src inhibitors in combination with
        pyrimidylaminobenzamides for treatment of leukemia)
IT   152459-95-5   172889-26-8   302962-49-8, Dasatinib 380843-75-4,
     Bosutinib   497152-38-2   641571-10-0
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (use of c-Src inhibitors in combination with pyrimidylaminobenzamides
        for treatment of leukemia)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

     (FILE 'HOME' ENTERED AT 17:00:01 ON 27 APR 2008)

     FILE 'REGISTRY' ENTERED AT 17:00:17 ON 27 APR 2008
L1            1 S SKI-606
L2            1 S "SKI 606"

     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 17:04:21 ON
     27 APR 2008
L3          235 S L2

=> s l3 and ischemia
L4            6 L3 AND ISCHEMIA

=> s l3 and ("myocardial infarction")
   1 FILES SEARCHED...
L5            2 L3 AND ("MYOCARDIAL INFARCTION")

=>

=> s l3 and angina
L6            1 L3 AND ANGINA

=> dup rem l4 l5  l6
PROCESSING COMPLETED FOR L4
PROCESSING COMPLETED FOR L5
```

PROCESSING COMPLETED FOR L6
L7 6 DUP REM L4 L5 L6 (3 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE CAPLUS
ANSWERS '4-6' FROM FILE EMBASE

=> d l7 1-6 hitstr ibib all

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
IT 380843-75-4, SKI-606
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
RN 380843-75-4 CAPLUS
CN 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2006:1209968 CAPLUS
DOCUMENT NUMBER: 145:500096
TITLE: Method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction
INVENTOR(S): Cheresh, David A.; Paul, Robert; Eliceiri, Brian
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41pp., Cont.-in-part of U.S. Ser. No. 298,377.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060258686	A1	20061116	US 2005-535325	20050518
WO 9961590	A1	19991202	WO 1999-US11780	19990528

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6685938 B1 20040203 US 1999-470881 19991222
US 20030130209 A1 20030710 US 2002-298377 20021118
WO 2004045563 A2 20040603 WO 2003-US37653 20031118
WO 2004045563 A3 20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-87220P P 19980529
WO 1999-US11780 A2 19990528
US 1999-470881 A2 19991222
US 2000-538248 A2 20000329
US 2002-298377 A2 20021118
WO 2003-US37653 W 20031118

AN 2006:1209968 CAPLUS
DN 145:500096
ED Entered STN: 17 Nov 2006
TI Method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction
IN Cheresh, David A.; Paul, Robert; Eliceiri, Brian
PA USA
SO U.S. Pat. Appl. Publ., 41pp., Cont.-in-part of U.S. Ser. No. 298,377.
CODEN: USXXCO
DT Patent
LA English
INCL 514262100
CC 1-8 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20060258686	A1	20061116	US 2005-535325	20050518
WO 9961590	A1	19991202	WO 1999-US11780	19990528

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6685938 B1 20040203 US 1999-470881 19991222
US 20030130209 A1 20030710 US 2002-298377 20021118
WO 2004045563 A2 20040603 WO 2003-US37653 20031118
WO 2004045563 A3 20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-87220P P 19980529
WO 1999-US11780 A2 19990528
US 1999-470881 A2 19991222
US 2000-538248 A2 20000329
US 2002-298377 A2 20021118
WO 2003-US37653 W 20031118

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20060258686	INCL	514262100
	IPCI	A61K0031-519 [I,A]
	IPCR	A61K0031-519 [I,C]; A61K0031-519 [I,A]
	NCL	514/262.100
WO 9961590	IPCI	C12N0009-00 [ICM,6]
	IPCR	C12N0015-09 [I,C*]; C12N0015-09 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0048-00 [I,C*]; A61K0048-00 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C12N0009-12 [I,C*]; C12N0009-12 [I,A]
	ECLA	C12N009/12
US 6685938	IPCI	A61K0038-45 [ICM,7]; A61K0038-43 [ICM,7,C*]; A61K0038-17 [ICS,7]; C12N0009-12 [ICS,7]
	IPCR	A01K0067-027 [I,C*]; A01K0067-027 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0038-43 [I,C*]; A61K0038-45 [I,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C12N0009-12 [I,C*]; C12N0009-12 [I,A]
	NCL	424/094.500; 435/194.000; 514/012.000
	ECLA	A01K067/027B; A61K038/45; C12N009/12
US 20030130209	IPCI	A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0031-519 [ICS,7]
	IPCR	A61K0038-43 [I,A]; A01K0067-027 [I,C*]; A01K0067-027 [I,A]; A61K0031-7088 [I,C*]; A61K0031-7088 [I,A]; A61K0035-66 [I,C*]; A61K0035-76 [I,A]; A61K0038-43 [I,C*]; A61K0038-45 [I,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; A61P0007-00 [I,C*]; A61P0007-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-08 [I,A]; A61P0009-10 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-02 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
	NCL	514/028.000; 514/262.100; 514/264.100; 514/265.100
	ECLA	A01K067/027B; A61K038/45
WO 2004045563	IPCI	A61K [ICM,7]
	IPCR	A61K0031-519 [I,C*]; A61K0031-519 [I,A]

AB Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase inhibitor. The invention also discloses the use of such inhibitors for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family

tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.

ST Src family tyrosine kinase inhibitor myocardial infarction treatment; pyrazolopyrimidine Src inhibitor myocardial infarction treatment; macrocyclic dienone Src inhibitor myocardial infarction treatment; pyridopyrimidine Src inhibitor myocardial infarction treatment; anilinoquinolinecarbonitrile Src inhibitor myocardial infarction treatment

IT Anti-ischemic agents
Cardiovascular agents
Drug delivery systems
Human
Platelet activation
Prophylaxis
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Src; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Platelet (blood)
(adhesion; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Ischemia
(cardiac; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Ischemia
(cerebral focal; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Blood vessel
(endothelium; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Heart, disease
(infarction; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(injections, i.p.; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(injections, i.v.; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Brain, disease
(ischemia, focal; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Heart, disease
(ischemia; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Macrocyclic compounds
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(macrocyclic dienones; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(oral; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(parenterals; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Blood vessel
(permeability; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Biological transport
(permeation, vascular; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
IT Adhesion, biological
(platelet; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
IT Endothelium
(vascular; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
IT Drugs
(veterinary; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
IT 127464-60-2, VEGF 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
IT 254-61-5D, Pyrido[2,3-d]pyrimidine, derivs. 12772-57-5, Radicicol R2146 30562-34-6, Geldanamycin 70563-58-5, Herbimycin A 172889-26-8 172889-27-9 260415-63-2, PD173955 380843-75-4, SKI-606 681215-57-6D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)
IT 915172-93-9 915172-95-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction)
IT 915172-94-0 915172-96-2
RL: PRP (Properties)
(unclaimed protein sequence; method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction)

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
IT 380843-75-4, SKI-606
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
RN 380843-75-4 CAPLUS
CN 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2004:331894 CAPLUS
DOCUMENT NUMBER: 140:350577
TITLE: Inhibition of src family kinases for the treatment of reperfusion injury related to revascularization
INVENTOR(S): Losordo, Douglas W.
PATENT ASSIGNEE(S): Caritas St. Elisabeth's Medical Center of Boston, Inc., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004032709	A2	20040422	WO 2003-US31430		20031003
WO 2004032709	A3	20041007			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2500368	A1	20040422	CA 2003-2500368		20031003
AU 2003279795	A1	20040504	AU 2003-279795		20031003
US 20060167021	A1	20060727	US 2005-530038		20050401
PRIORITY APPLN. INFO.:			US 2002-416334P	P	20021004
			WO 2003-US31430	W	20031003

AN 2004:331894 CAPLUS
DN 140:350577
ED Entered STN: 23 Apr 2004
TI Inhibition of src family kinases for the treatment of reperfusion injury related to revascularization
IN Losordo, Douglas W.
PA Caritas St. Elisabeth's Medical Center of Boston, Inc., USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61B
CC 1-8 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004032709	A2	20040422	WO 2003-US31430	20031003
WO 2004032709	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	CA 2500368	A1	20040422	CA 2003-2500368	20031003
	AU 2003279795	A1	20040504	AU 2003-279795	20031003
	US 20060167021	A1	20060727	US 2005-530038	20050401
PRAI	US 2002-416334P	P	20021004		
	WO 2003-US31430	W	20031003		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004032709	ICM	A61B
	IPCI	A61B [ICM,7]
	IPCR	A61B [I,S]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]
CA 2500368	IPCI	A61K0031-47 [ICM,7]
	IPCR	A61B [I,S]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]
AU 2003279795	IPCI	A61K0031-47 [ICM,7]
	IPCR	A61B [I,S]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]
US 20060167021	IPCI	A61K0031-519 [I,A]; A61K0031-47 [I,A]
	IPCR	A61K0031-519 [I,A]; A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-519 [I,C]
	NCL	514/262.100; 514/313.000

AB The invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability. The inhibitors of the invention include inhibitors of src family kinases.

ST VEGF mediated vascular permeability inhibitor revascularization reperfusion injury treatment; src kinase inhibitor revascularization reperfusion injury treatment

IT Heart, disease
(angina pectoris, reperfusion injury from; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Medical goods
(angioplasty balloon, coating for; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Edema
Ischemia
(cardiac; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Cardiovascular agents
Cytoprotective agents
(cardioprotective agents; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Disease, animal
(compartment syndrome; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Artery
(coronary, coronary revascularization procedure; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Heart, disease
(edema; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Cadherins
Catenins
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(flk-cadherin-catenin complex; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Heart, disease
(infarction, reperfusion injury from; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT Drug delivery systems
(infusions; src family kinase inhibitors for treatment of reperfusion

injury related to revascularization)
IT Drug delivery systems
(injections, i.p.; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Drug delivery systems
(injections, i.v.; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Drug delivery systems
(injections; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Reperfusion
(injury; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Drug delivery systems
(intracoronary; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Heart, disease
(ischemia; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Blood vessel, disease
(occlusion; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Drug delivery systems
(percutaneous; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Blood vessel
(permeability, VEGF-mediated; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Biological transport
(permeation, vascular, VEGF-mediated; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Disease, animal
(post-pump syndrome; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Ischemia
(reperfusion injury after; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Injury
(reperfusion; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Drug delivery systems
(solns., cardioplegic; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Angioplasty
Anti-ischemic agents
Atherectomy
Cardiovascular agents
Coronary bypass surgery
(src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Medical goods
(stents, stent placement; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT Brain, disease
(stroke; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)
IT 172889-26-8, PP 1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PP 1; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT 114051-78-4, Lck kinase 140208-17-9, Lyn kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase 145539-86-2, Hck kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT 34846-64-5D, 3-Quinolinecarbonitrile, derivs. 64850-00-6D, Quinolinecarbonitrile, derivs. 172889-27-9, PP2 380843-75-4, SKI-606 681215-57-6D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vascular permeability mediated by; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

IT 380843-75-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Src inhibitor; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

RN 380843-75-4 CAPLUS

CN 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2004:740166 CAPLUS
DOCUMENT NUMBER: 141:243354
TITLE: Preparation of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles as Src inhibitors for the treatment of ischemic injury
INVENTOR(S): Boschelli, Diane Harris; Zaleska, Margaret Maria; Boschelli, Frank Charles; Arndt, Kim Timothy
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075898	A1	20040910	WO 2004-US4904	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040229880	A1	20041118	US 2004-780973	20040218
AU 2004216235	A1	20040910	AU 2004-216235	20040219
CA 2516418	A1	20040910	CA 2004-2516418	20040219
EP 1594502	A1	20051116	EP 2004-712889	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007441	A	20060131	BR 2004-7441	20040219
CN 1750824	A	20060322	CN 2004-80004674	20040219
JP 2006522023	T	20060928	JP 2006-503706	20040219
IN 2005KN01564	A	20070126	IN 2005-KN1564	20050808
MX 2005PA08706	A	20051005	MX 2005-PA8706	20050816
NO 2005004070	A	20051114	NO 2005-4070	20050901
PRIORITY APPLN. INFO.:			US 2003-449316P	P 20030221
			WO 2004-US4904	A 20040219

OTHER SOURCE(S): MARPAT 141:243354

AN 2004:740166 CAPLUS

DN 141:243354

ED Entered STN: 10 Sep 2004

TI Preparation of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles as Src inhibitors for the treatment of ischemic injury

IN Boschelli, Diane Harris; Zaleska, Margaret Maria; Boschelli, Frank Charles; Arndt, Kim Timothy

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-496
ICS A61K031-4709; A61K031-4706; A61P009-10

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004075898	A1	20040910	WO 2004-US4904	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040229880	A1	20041118	US 2004-780973	20040218
AU 2004216235	A1	20040910	AU 2004-216235	20040219
CA 2516418	A1	20040910	CA 2004-2516418	20040219
EP 1594502	A1	20051116	EP 2004-712889	20040219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR	2004007441	A	20060131	BR 2004-7441	20040219
CN	1750824	A	20060322	CN 2004-80004674	20040219
JP	2006522023	T	20060928	JP 2006-503706	20040219
IN	2005KN01564	A	20070126	IN 2005-KN1564	20050808
MX	2005PA08706	A	20051005	MX 2005-PA8706	20050816
NO	2005004070	A	20051114	NO 2005-4070	20050901
PRAI US	2003-449316P	P	20030221		
WO	2004-US4904	A	20040219		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004075898	ICM	A61K031-496
	ICS	A61K031-4709; A61K031-4706; A61P009-10
	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-4706 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211; M07D
US 20040229880	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	NCL	514/253.060; 514/313.000
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211
AU 2004216235	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-4706 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
CA 2516418	IPCI	A61K0031-496 [ICM,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]; A61K0031-4706 [ICS,7]; A61K0031-4709 [ICS,7]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211
EP 1594502	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-4706 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54;

		C07D401/04+215+211
BR 2004007441	IPCI	A61K0031-496 [ICS,7]; A61K0031-4706 [ICS,7]; A61K0031-4709 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4709 [I,C*]; A61K0031-496 [I,C*]; C07D0215-00 [I,C*]; C07D0401-00 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,A]; A61K0031-496 [I,A]; C07D0215-54 [I,A]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211
CN 1750824	IPCI	A61K0031-496 [I,A]; A61K0031-4709 [I,A]; A61K0031-4706 [I,A]; A61P0009-10 [I,A]; A61P0009-00 [I,C*]
	IPCR	A61K0031-496 [I,A]; A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211
JP 2006522023	IPCI	A61K0031-4709 [I,A]; A61P0009-10 [I,A]; A61P0009-00 [I,C*]; A61P0025-00 [I,A]; A61P0043-00 [I,A]; C07D0215-54 [N,A]; C07D0215-00 [N,C*]; C12N0015-09 [N,A]; C07D0401-12 [N,A]; C07D0401-00 [N,C*]
	IPCR	A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C]; A61P0009-10 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-12 [N,A]; C12N0015-09 [N,C]; C12N0015-09 [N,A]
	FTERM	4B024/AA11; 4B024/BA10; 4B024/CA04; 4B024/CA20; 4B024/DA02; 4B024/EA04; 4B024/HA11; 4C031/NA05; 4C063/AA01; 4C063/BB08; 4C063/CC14; 4C063/DD10; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA04; 4C086/BC28; 4C086/GA12; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA36; 4C086/ZC20
IN 2005KN01564	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
MX 2005PA08706	IPCI	A61K0031-4706 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-496 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
NO 2005004070	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211

OS MARPAT 141:243354

GI



I



II

AB Title compds. I [wherein X = N, CH; n = 1-3; R', R = independently C1-3 alkyl; with the proviso that when n = 1, X ≠ N; and pharmaceutically acceptable salts thereof] were prepared as Src inhibitors. Compds. of the invention and their pharmaceutical compns. provide neuroprotection, inhibit neurol. deficits, reduce infarct vols., and inhibit post-ischemic vascular permeability following an ischemic event. For example, amination of 7-(3-chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarbonitrile with N-methylpiperazine provided II (75%). The latter suppressed Src tyrosine kinase activity (IC50 = 1.2 nM) and inhibited Src dependent cell proliferation in Rat2 fibroblasts stably transformed with a plasmid containing the catalytic domain of human c-Src (IC50 = 100 nM). In a transient model of focal ischemia using Wistar rats, administration of II at doses of 3, 10, and 30 mg/kg (IV) resulted in reduction of brain tissue infarction volume by 22%, 53%, and 42%, resp., and reduction of stroke-induced neurol. deficits as measured by mean motor deficit scores. In a model producing extensive infarction to sensorimotor cortex with quant. assessment of neurol. deficits for 21 days post-stroke, II provided significant improvement in the neurol. outcome.

ST quinolinecarbonitrile prepn Src inhibitor ischemic injury treatment neuroprotectant

IT Heart, disease
(arrest; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Brain, disease
(hemorrhagic stroke; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Brain, disease
(infarction; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Drug delivery systems
(injections, i.v.; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Brain, disease

(ischemia, transient; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Cytoprotective agents
Nervous system agents
(neuroprotective agents; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Asphyxia
(perinatal; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Blood vessel
(permeability; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Anti-ischemic agents
Drug delivery systems
Human
Hypoxia
Ischemia
(preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Epilepsy
(status epilepticus; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Brain, disease
(stroke; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Ischemia
(transient cerebral; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT Head and Neck, disease
Spinal cord, disease
(trauma; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
IT 380843-75-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
380843-76-5P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[3-(4-ethyl-1-piperazinyl)propoxy]-6-methoxy-3-quinolinecarbonitrile 380843-79-8P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile 622368-88-1P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile 622368-91-6P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile 622369-21-5P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile 622369-25-9P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile 753005-88-8P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-quinolinecarbonitrile
753005-89-9P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-3-quinolinecarbonitrile 753005-90-2P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 753005-91-3P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile 753005-92-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
753005-93-5P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile 753005-94-6P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]quinoline-3-carbonitrile 753005-95-7P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Src inhibitor; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT 622369-35-1P, Ethyl 7-fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate 622369-36-2P, 7-Fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid 622369-37-3P, 7-Fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxamide 622369-38-4P, 7-Fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarbonitrile 622369-40-8P, 4-Chloro-7-fluoro-6-methoxy-3-quinolinecarbonitrile 622369-46-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-fluoro-6-methoxy-3-quinolinecarbonitrile 622369-50-0P, 6-Benzyloxy-7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile 622369-51-1P, 6-Benzyloxy-4-chloro-7-fluoro-3-quinolinecarbonitrile 622369-52-2P, 4-Chloro-7-fluoro-6-hydroxy-3-quinolinecarbonitrile 622369-53-3P, 4-Chloro-6-ethoxy-7-fluoro-3-quinolinecarbonitrile 622369-82-8P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-fluoro-3-quinolinecarbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT 141349-89-5, Src kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT 87-13-8, Diethyl (ethoxymethylene)malonate 94-05-3, Ethyl 2-(ethoxymethylene)-2-cyanoacetate 109-01-3, N-Methylpiperazine 366-99-4, 3-Fluoro-4-methoxyaniline 5308-25-8, N-Ethylpiperazine 5317-33-9, 3-(4-Methylpiperazin-1-yl)propanol 5464-12-0, 2-(4-Methyl-1-piperazinyl)ethanol 7037-30-1, 3-(1-Methyl-4-piperidinyl)propanol 20691-89-8, 1-Methylpiperidine-4-methanol 21156-84-3, 1-Methyl-4-piperidineethanol 21867-64-1, N-Propylpiperazine 98446-49-2, 2,4-Dichloro-5-methoxyaniline 168268-00-6, 4-Benzyloxy-3-fluoroaniline 380844-42-8, 7-(2-Chloroethoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarbonitrile 380844-49-5, 7-(3-Chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarbonitrile 622369-81-7, 3-(4-Ethylpiperazin-1-yl)propanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) American Home Products Co; US 2002026052 A1 2002
(2) Berger, D; BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 2001, V12(20), P2989
(3) Boschelli, D; BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 2003, V13(21), P3797 CAPLUS
(4) Caritas St Elisabeth's Medical Centre Of Boston Inc; WO 2004032709 A 2004 CAPLUS
(5) Paul, R; NATURE MEDICINE 2001, V7(2), P222 CAPLUS
(6) Wyeth Holdings Co; WO 03093241 A 2003 CAPLUS

L7 ANSWER 4 OF 6 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN DUPLICATE 2

ACCESSION NUMBER: 2006365755 EMBASE
TITLE: Src protein tyrosine kinase family and acute inflammatory responses.
AUTHOR: Liu, Mingyao (correspondence)
CORPORATE SOURCE: School of Graduate Studies, Univ. of Toronto, 65 St. George St., Toronto, Ont. M5S 2Z9, Canada. mingyao.liu@utoronto.ca
AUTHOR: Okutani, Daisuke; Lodyga, Monika; Han, Bing

SOURCE: American Journal of Physiology - Lung Cellular and Molecular Physiology, (2006) Vol. 291, No. 2, pp. L129-L141.
Refs: 154
ISSN: 1040-0605 E-ISSN: 1522-1504 CODEN: APLPE7
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
005 General Pathology and Pathological Anatomy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 15 Aug 2006
Last Updated on STN: 15 Aug 2006

AN 2006365755 EMBASE

TI Src protein tyrosine kinase family and acute inflammatory responses.

AU Liu, Mingyao (correspondence)
CS School of Graduate Studies, Univ. of Toronto, 65 St. George St., Toronto, Ont. M5S 2Z9, Canada. mingyao.liu@utoronto.ca
AU Okutani, Daisuke; Lodyga, Monika; Han, Bing

SO American Journal of Physiology - Lung Cellular and Molecular Physiology, (2006) Vol. 291, No. 2, pp. L129-L141.
Refs: 154
ISSN: 1040-0605 E-ISSN: 1522-1504 CODEN: APLPE7
CY United States
DT Journal; General Review; (Review)
FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
005 General Pathology and Pathological Anatomy
LA English
SL English
ED Entered STN: 15 Aug 2006
Last Updated on STN: 15 Aug 2006

AB Acute inflammatory responses are one of the major underlying mechanisms for tissue damage of multiple diseases, such as ischemia -reperfusion injury, sepsis, and acute lung injury. By use of cellular and molecular approaches and transgenic animals, Src protein tyrosine kinase (PTK) family members have been identified to be essential for the recruitment and activation of monocytes, macrophages, neutrophils, and other immune cells. Src PTKs also play a critical role in the regulation of vascular permeability and inflammatory responses in tissue cells. Importantly, animal studies have demonstrated that small chemical inhibitors for Src PTKs attenuate tissue injury and improve survival from a variety of pathological conditions related to acute inflammatory responses. Further investigation may lead to the clinical application of these inhibitors as drugs for ischemia-reperfusion injury (such as stroke and myocardial infarction), sepsis, acute lung injury, and multiple organ dysfunction syndrome. Copyright .COPYRGT. 2006 the American Physiological Society.

CT Medical Descriptors:
acute lung injury: DT, drug therapy
antiinflammatory activity
blood vessel permeability
brain injury: DT, drug therapy
brain ischemia: DT, drug therapy
drug inhibition
drug protein binding

endotoxemia
epithelium cell
heart infarction: DT, drug therapy
human
*inflammation
  ischemia
leukocyte activation
lung transplantation
macrophage activation
*multiple organ failure
nonhuman
priority journal
reperfusion injury
*respiratory distress
review
sepsis
spinal cord compression: DT, drug therapy
stroke: DT, drug therapy
virus infection
CT Drug Descriptors:
2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole 5 sulfonic acid dimethylamide: DT, drug therapy
2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole 5 sulfonic acid dimethylamide: IP, intraperitoneal drug administration
2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole 5 sulfonic acid dimethylamide: PD, pharmacology
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 1: DT, drug therapy
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 1: IP, intraperitoneal drug administration
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 1: PD, pharmacology
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2: DT, drug therapy
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2: IP, intraperitoneal drug administration
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2: IV, intravenous drug administration
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2: PD, pharmacology
azm 475271: PD, pharmacology
bosutinib: PD, pharmacology
CD14 antigen: EC, endogenous compound
cgp 76030: PD, pharmacology
cgp 77675: PD, pharmacology
cytokine: EC, endogenous compound
gamma interferon: EC, endogenous compound
hematopoietic cell kinase: EC, endogenous compound
immunoglobulin enhancer binding protein: EC, endogenous compound
interleukin 1: EC, endogenous compound
interleukin 6: EC, endogenous compound
m 47271
m 475271: PD, pharmacology
mitogen activated protein kinase 1: EC, endogenous compound
mitogen activated protein kinase 3: EC, endogenous compound
protein kinase: EC, endogenous compound
protein kinase Blk: EC, endogenous compound
protein kinase fgr: EC, endogenous compound
protein kinase Fyn: EC, endogenous compound
protein kinase Lck: EC, endogenous compound
protein kinase Lyn: EC, endogenous compound

protein kinase Yes: EC, endogenous compound
protein kinase Yrk: EC, endogenous compound
*protein tyrosine kinase: EC, endogenous compound
*protein tyrosine kinase inhibitor: DT, drug therapy
*protein tyrosine kinase inhibitor: IP, intraperitoneal drug administration
*protein tyrosine kinase inhibitor: IV, intravenous drug administration
*protein tyrosine kinase inhibitor: PD, pharmacology
toll like receptor 4: EC, endogenous compound
tumor necrosis factor alpha: EC, endogenous compound
unclassified drug
vasculotropin: EC, endogenous compound

RN (bosutinib) 380843-75-4; (gamma interferon) 82115-62-6; (mitogen activated protein kinase 1) 137632-08-7; (mitogen activated protein kinase 3) 137632-07-6; (protein kinase Fyn) 141349-87-3; (protein kinase Lck) 114051-78-4; (protein kinase Lyn) 140208-17-9; (protein kinase) 9026-43-1; (protein tyrosine kinase) 80449-02-1; (toll like receptor 4) 203811-83-0; (vasculotropin) 127464-60-2

CN azm 475271; cgp 76030; cgp 77675; m 47271; ski 606; su 6656

L7 ANSWER 5 OF 6 EMBASE

ACCESSION NUMBER: 2007392630 EMBASE
TITLE: Bosutinib. Dual Src and Abl kinase inhibitor treatment of solid tumors treatment of CML and Ph(+) all.
AUTHOR: Boschelli, Diane H. (correspondence); Boschelli, Frank
CORPORATE SOURCE: Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10956, United States.
SOURCE: Drugs of the Future, (Jun 2007) Vol. 32, No. 6, pp. 481-490.
Refs: 64
ISSN: 0377-8282 CODEN: DRFUD4
COUNTRY: Spain
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
025 Hematology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 23 Aug 2007
Last Updated on STN: 23 Aug 2007

AN 2007392630 EMBASE
TI Bosutinib. Dual Src and Abl kinase inhibitor treatment of solid tumors treatment of CML and Ph(+) all.
AU Boschelli, Diane H. (correspondence); Boschelli, Frank
CS Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10956, United States.
SO Drugs of the Future, (Jun 2007) Vol. 32, No. 6, pp. 481-490.
Refs: 64
ISSN: 0377-8282 CODEN: DRFUD4
CY Spain
DT Journal; Article
FS 016 Cancer
025 Hematology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English

ED Entered STN: 23 Aug 2007
Last Updated on STN: 23 Aug 2007

AB Bosutinib (SKI-606) is a potent inhibitor of Src kinase activity, having IC(50) values of 1-3 nM in isolated Src enzyme assays. Bosutinib inhibits Src autophosphorylation and the phosphorylation of several known Src substrate proteins in multiple human cancer lines. Bosutinib is orally effective in nude mouse xenograft models, including HT-29, COLO 205, HCT 116 and DLD-1 colorectal tumors and MDA-MB-231 breast tumors, as well as in several in vivo models of metastasis. Like many other Src inhibitors, bosutinib is also a potent inhibitor of Abl kinase activity, having an IC(50) of 1 nM in an enzyme assay. It is a potent antiproliferative agent in chronic myelogenous leukemia (CML) cell lines and inhibits the phosphorylation of Abl substrate proteins in these cells. A 5-day oral regimen of bosutinib caused tumor regression and some cures in a CML xenograft model. Bosutinib was also orally active in models of imatinib-resistant CML. Bosutinib is currently in clinical trials for the treatment of both solid tumors and CML.

CT Medical Descriptors:
article
bone metastasis: DT, drug therapy
brain ischemia: DT, drug therapy
breast metastasis: DT, drug therapy
breast tumor
chronic myeloid leukemia: DR, drug resistance
chronic myeloid leukemia: DT, drug therapy
clinical trial
colorectal tumor
diarrhea: SI, side effect
dose response
drug bioavailability
drug blood level
drug distribution
drug half life
drug metabolism
drug stability
drug structure
drug synthesis
human
lung edema: SI, side effect
nausea: SI, side effect
nonhuman
pleura effusion: SI, side effect
rash: SI, side effect
tumor regression
xenograft

CT Drug Descriptors:
Abelson kinase: EC, endogenous compound
*bosutinib: AE, adverse drug reaction
*bosutinib: CT, clinical trial
*bosutinib: AN, drug analysis
*bosutinib: CM, drug comparison
*bosutinib: CR, drug concentration
*bosutinib: DV, drug development
*bosutinib: DO, drug dose
*bosutinib: DT, drug therapy
*bosutinib: IP, intraperitoneal drug administration
*bosutinib: PK, pharmacokinetics
*bosutinib: PD, pharmacology
dasatinib: AE, adverse drug reaction
dasatinib: CM, drug comparison

dasatinib: DT, drug therapy
dasatinib: PD, pharmacology
fibroblast growth factor receptor: EC, endogenous compound
imatinib: AE, adverse drug reaction
imatinib: CM, drug comparison
imatinib: DT, drug therapy
imatinib: PD, pharmacology
platelet derived growth factor receptor: EC, endogenous compound
somatomedin C receptor: EC, endogenous compound
RN (bosutinib) 380843-75-4; (dasatinib) 302962-49-8; (fibroblast growth factor receptor) 153424-51-2; (imatinib) 152459-95-5, 220127-57-1
CN (1) gleevec; (2) glivec; (3) sprycel; ski 606
CO (1) Novartis; (2) Novartis; (3) Bristol Myers Squibb

L7 ANSWER 6 OF 6 EMBASE
ACCESSION NUMBER: 2008025607 EMBASE
TITLE: Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
AUTHOR: Mauro, Michael J., Dr. (correspondence)
CORPORATE SOURCE: Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239, United States. maurom@ohsu.edu
SOURCE: Current Treatment Options in Oncology, (Aug 2007) Vol. 8, No. 4, pp. 287-295.
Refs: 30
ISSN: 1527-2729 CODEN: CTOOBW
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
025 Hematology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Feb 2008
Last Updated on STN: 13 Feb 2008
AN 2008025607 EMBASE
TI Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
AU Mauro, Michael J., Dr. (correspondence)
CS Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239, United States. maurom@ohsu.edu
SO Current Treatment Options in Oncology, (Aug 2007) Vol. 8, No. 4, pp. 287-295.
Refs: 30
ISSN: 1527-2729 CODEN: CTOOBW
CY United States
DT Journal; General Review; (Review)
FS 016 Cancer
025 Hematology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
ED Entered STN: 13 Feb 2008
Last Updated on STN: 13 Feb 2008
CT Medical Descriptors:
arthralgia: SI, side effect
blast cell crisis: SI, side effect

blood toxicity: SI, side effect
bone marrow suppression: SI, side effect
cardiotoxicity: SI, side effect
*chronic myeloid leukemia: DR, drug resistance
*chronic myeloid leukemia: DT, drug therapy
clinical trial
diarrhea: SI, side effect
dosage schedule comparison
drug cross tolerance
drug dose comparison
drug efficacy
drug half life
drug induced headache: SI, side effect
drug megadose
drug penetration
drug response
drug tolerability
ECG abnormality: SI, side effect
edema: SI, side effect
fatigue: SI, side effect
fluid retention
gastrointestinal hemorrhage: SI, side effect
heart arrhythmia: SI, side effect
heart disease: SI, side effect
human
hyperglycemia: SI, side effect
hypocalcemia: SI, side effect
hypophosphatemia: SI, side effect
  ischemia: SI, side effect
*mutational analysis
myalgia: SI, side effect
neutropenia: SI, side effect
pancreatitis: SI, side effect
pleura effusion: DT, drug therapy
pleura effusion: SI, side effect
pleura effusion: SU, surgery
pruritus: SI, side effect
QT prolongation: SI, side effect
rash: SI, side effect
review
salvage therapy
side effect: SI, side effect
structure activity relation
subdural hematoma: SI, side effect
thorax drainage
thrombocytopenia: SI, side effect
treatment failure
CT Drug Descriptors:
4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: CT, clinical trial
4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: DT, drug therapy
4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: PK, pharmacokinetics
4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: PD, pharmacology
antineoplastic agent: CT, clinical trial
antineoplastic agent: DT, drug therapy
antineoplastic agent: PK, pharmacokinetics

```
     antineoplastic agent: PD, pharmacology
     BCR ABL protein: EC, endogenous compound
     bosutinib: AE, adverse drug reaction
     bosutinib: CT, clinical trial
     bosutinib: DT, drug therapy
     bosutinib: PD, pharmacology
     cyclopropanecarboxylic acid [4 [4 (4 methyl 1 piperazinyl) 6 (5 methyl 2h
     pyrazol 3 ylamino) 2 pyrimidinylthio]phenyl]amide: CT, clinical trial
     cyclopropanecarboxylic acid [4 [4 (4 methyl 1 piperazinyl) 6 (5 methyl 2h
     pyrazol 3 ylamino) 2 pyrimidinylthio]phenyl]amide: DT, drug therapy
     cytarabine: CT, clinical trial
     cytarabine: CM, drug comparison
     cytarabine: DT, drug therapy
     dasatinib: AE, adverse drug reaction
     dasatinib: CT, clinical trial
     dasatinib: CM, drug comparison
     dasatinib: CR, drug concentration
     dasatinib: DO, drug dose
     dasatinib: DT, drug therapy
     dasatinib: PK, pharmacokinetics
     dasatinib: PD, pharmacology
     diuretic agent: DT, drug therapy
     gamma interferon: CT, clinical trial
     gamma interferon: CM, drug comparison
     gamma interferon: DT, drug therapy
     *imatinib: CT, clinical trial
     *imatinib: CM, drug comparison
     *imatinib: DO, drug dose
     *imatinib: DT, drug therapy
     *imatinib: PD, pharmacology
     nilotinib: AE, adverse drug reaction
     nilotinib: CT, clinical trial
     nilotinib: CM, drug comparison
     nilotinib: DT, drug therapy
     nilotinib: PD, pharmacology
     *protein tyrosine kinase inhibitor: CT, clinical trial
     *protein tyrosine kinase inhibitor: DT, drug therapy
     *protein tyrosine kinase inhibitor: PD, pharmacology
     threonine: EC, endogenous compound
RN   (bosutinib) 380843-75-4; (cyclopropanecarboxylic acid [4 [4 (4
     methyl 1 piperazinyl) 6 (5 methyl 2h pyrazol 3 ylamino) 2
     pyrimidinylthio]phenyl]amide) 639089-54-6; (cytarabine) 147-94-4, 69-74-9;
     (dasatinib) 302962-49-8; (gamma interferon) 82115-62-6; (imatinib)
     152459-95-5, 220127-57-1; (nilotinib) 641571-10-0; (threonine) 36676-50-3,
     72-19-5
CN   amn 107; ara C; bms 354825; inno 406; ski 606; sti 571


=> d his

     (FILE 'HOME' ENTERED AT 17:00:01 ON 27 APR 2008)

     FILE 'REGISTRY' ENTERED AT 17:00:17 ON 27 APR 2008
L1            1 S SKI-606
L2            1 S "SKI 606"

     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 17:04:21 ON
     27 APR 2008
L3          235 S L2
L4            6 S L3 AND ISCHEMIA
L5            2 S L3 AND ("MYOCARDIAL INFARCTION")
```

L6 1 S L3 AND ANGINA
L7 6 DUP REM L4 L5 L6 (3 DUPLICATES REMOVED)